Abstract

Factors that contribute to the transmission of human immunodeficiency virus type 1 (HIV-1), especially drug-resistant HIV-1 variants remain a significant public health concern. In-depth phylogenetic analyses of viral sequences obtained in the screening phase from antiretroviral-naïve HIV-infected patients seeking enrollment in EPZ108859, a large open-label study in the USA, Canada and Puerto Rico (ClinicalTrials.gov NCT00440947) were examined for insights into the roles of drug resistance and epidemiological factors that could impact disease dissemination. Viral transmission clusters (VTCs) were initially predicted from a phylogenetic analysis of population level HIV-1 pol sequences obtained from 690 antiretroviral-naïve subjects in 2007. Subsequently, the predicted VTCs were tested for robustness by ultra deep sequencing (UDS) using pyrosequencing technology and further phylogenetic analyses. The demographic characteristics of clustered and non-clustered subjects were then compared. From 690 subjects, 69 were assigned to 1 of 30 VTCs, each containing 2 to 5 subjects. Race composition of VTCs were significantly more likely to be white (72% vs. 60%; p = 0.04). VTCs had fewer reverse transcriptase and major PI resistance mutations (9% vs. 24%; p = 0.002) than non-clustered sequences. Both men-who-have-sex-with-men (MSM) (68% vs. 48%; p = 0.001) and Canadians (29% vs. 14%; p = 0.03) were significantly more frequent in VTCs than non-clustered sequences. Of the 515 subjects who initiated antiretroviral therapy, 33 experienced confirmed virologic failure through 144 weeks while only 3/33 were from VTCs. Fewer VTCs subjects (as compared to those with non-clustering virus) had HIV-1 with resistance-associated mutations or experienced virologic failure during the course of the study. Our analysis shows specific geographical and drug resistance trends that correlate well with transmission clusters defined by HIV sequences of similarity. Furthermore, our study demonstrates the utility of molecular and epidemiological analysis of VTCs for identifying population-specific risks associated with HIV-1 transmission and developing effective local healthcare strategies.

Highlights

  • With the availability of highly active antiretroviral therapy (HAART) transmission of drug resistant human immunodeficiency virus type 1 (HIV-1) quasi-species has become of increasing concern

  • HIV reverse transcriptase (RT) and protease population genotyping was prospectively attempted using plasma samples collected from 726 subjects who were initially screened for the study

  • HIV population genotype was obtained from a total of 690 unique ART-naıve subjects from sites located in the continental United States, Puerto Rico and Canada and an appropriate genotype was a requirement for later study enrollment

Read more

Summary

Introduction

With the availability of highly active antiretroviral therapy (HAART) transmission of drug resistant human immunodeficiency virus type 1 (HIV-1) quasi-species has become of increasing concern. The viral sequence interrelationships and epidemiological data from antiviral-naıve subjects seeking treatment can provide a framework for better understanding the population dynamics behind drug resistant virus and of HIV-1 transmission networks which may span large geographic regions. In this study we used a phylogenetic approach to identify VTCs in ART-naıve subjects infected with highly related HIV. These subjects, from the continental United States (USA), Canada and Puerto Rico, were seeking HAART treatment through enrollment in the open-label, randomized clinical trial ARIES (Atazanavir-Ritonavir Induction with Epzicom Study; EPZ108859) [25,26,27]. Responses to therapy for subjects from VTCs were compared to those subjects with non-clustered sequences to better understand the population dynamics behind the spread of HIV infection within study subjects and aid in future design of treatment strategies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call